Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.32 - $55.57
Previous CloseN/A
Volume110.15K
Average Volume (3M)1.16M
Market Cap
$366.61M
Enterprise Value$313.89M
Total Cash (Recent Filing)$227.49M
Total Debt (Recent Filing)$11.71M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Nov 06, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding40,915,962
10 Day Avg. Volume964,391
30 Day Avg. Volume1,160,441
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-8.90
Forecast
1Y Price Target
$8.94Price Target Upside-5.80% Downside
Rating ConsensusHold
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Demographic TrendsManagement highlighted encouraging demographic shifts, including a younger cataract patient population who tend to be more sensitive to quality of vision issues.
Growth OpportunitiesManagement believes expansion of its US commercial pivot and recent OUS launches could become areas of growth.
Market AdoptionWith strong clinical outcomes that support LAL adoption and expand the overall premium IOL market, the company maintains an optimistic longer term.
Bears Say
Financial PerformanceRXST preannounced Q2 revenue of $33.6m, missing Street consensus by $6m or 16%.
Market PressuresRXST is likely also impacted by a softer IOL market and increased competitive pressures from recent multifocal IOL launches.
Revenue GuidanceRXST cut 2025 revenue guidance by 25% after cutting it 12% in Q1.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $6.32 and its highest was $55.57 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $366.61M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Aug 07, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.036.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Overvalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.37.
How many shares outstanding does RxSight have?
RxSight has 40,915,962 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -7.702%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.94 (-5.80% Downside)
$8.94 (-5.80% Downside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 760.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.47%
12-Months-Change
Fundamentals
Return on Equity
-11.66%
Trailing 12-Months
Asset Growth
1.15%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive aspects such as increased LAL revenue, improved gross margin, and international market expansion. However, significant challenges were noted including overall revenue decline, decreased LDD sales, increased net loss, and higher operating expenses. The guidance for a revenue decline further contributed to the cautious outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$8.94
▼(-5.80% Downside)
Technical Analysis
Ownership Overview
5.57% Insiders
17.16% Mutual Funds
35.92% Other Institutional Investors
25.09% Public Companies and
Individual Investors